Literature DB >> 7815285

Pharmacokinetic characteristics of 5-fluorouracil and mitomycin C in intraperitoneal chemotherapy.

T Kuzuya1, M Yamauchi, A Ito, M Hasegawa, T Hasegawa, T Nabeshima.   

Abstract

Eight patients with malignancies confined to the peritoneal space participated in this study. Five hundred milligrams 5-fluorouracil or 10 mg mitomycin C was diluted in 1 L saline. The mixed solution was injected intraperitoneally through the semi-permanent peritoneal catheter. Blood and peritoneal fluid were collected after injection. 5-Fluorouracil concentrations in the peritoneal fluid were 1000 times those in serum, while mitomycin C concentrations were 100 times those in serum. Areas under the concentration vs time curve (AUC) were calculated by the trapezoidal method with extrapolation to infinity. The ratio of peritoneal fluid AUC to serum AUC was about 1400 for 5-fluorouracil and 80 for mitomycin C. Patterns for the absorption and elimination from systemic circulation were similar for both compounds. Drug concentrations in the peritoneal fluid and serum were analysed according to the compartment model. The half-life in the peritoneal fluid (t1/2p) and the rate constant from the peritoneal fluid to the systemic circulation (ka) were nearly equal for both 5-fluorouracil and mitomycin C (t1/2p, 1.0 h for 5-fluorouracil and 1.3 h for mitomycin C; ka 0.71 h-1 for 5-fluorouracil and 0.68 h-1 for mitomycin C), although the apparent volume of distribution (Vds/F) and clearance in the peritoneal cavity (CLp) for mitomycin C (78 L m-2 and 1.8 L h-1 m-2) were about twice the values for 5-fluorouracil (149 L m-2 and 0.8 L h-1 m-2).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7815285     DOI: 10.1111/j.2042-7158.1994.tb03883.x

Source DB:  PubMed          Journal:  J Pharm Pharmacol        ISSN: 0022-3573            Impact factor:   3.765


  14 in total

Review 1.  Cytoreductive surgery and intraoperative intraperitoneal hyperthermic chemotherapy in patients with peritoneal carcinomatosis of colorectal origin.

Authors:  César P Ramírez Plaza; Manuel A Cobo Dols; Alberto Gómez Portilla; Agustín de la Fuente Perucho
Journal:  Clin Transl Oncol       Date:  2005-11       Impact factor: 3.405

Review 2.  Management of peritoneal carcinomatosis from colorectal cancer.

Authors:  Chukwuemeka U Ihemelandu; Perry Shen; John H Stewart; Konstantinos Votanopoulos; Edward A Levine
Journal:  Semin Oncol       Date:  2011-08       Impact factor: 4.929

3.  Splenectomy revisited in 2011: Impact on hematologic toxicities while performing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.

Authors:  Nancy Deslauriers; Harold Olney; Rami Younan
Journal:  J Gastrointest Oncol       Date:  2011-06

4.  A comparison of hematologic toxicity profiles after heated intraperitoneal chemotherapy with oxaliplatin and mitomycin C.

Authors:  Konstantinos Votanopoulos; Chukwuemeka Ihemelandu; Perry Shen; John Stewart; Gregory Russell; Edward A Levine
Journal:  J Surg Res       Date:  2012-03-10       Impact factor: 2.192

5.  Hyperthermic intraperitoneal chemotherapy with mitomycin C and 5-fluorouracil in patients at high risk of peritoneal metastasis from colorectal cancer: A preliminary clinical study.

Authors:  Tomoharu Shimizu; Satoshi Murata; Hiromichi Sonoda; Eiji Mekata; Hiroyuki Ohta; Katsushi Takebayashi; Tohru Miyake; Tohru Tani
Journal:  Mol Clin Oncol       Date:  2014-01-16

Review 6.  Cytoreductive Surgery plus HIPEC for Peritoneal Metastases from Colorectal Cancer.

Authors:  Aditi Bhatt; Diane Goéré
Journal:  Indian J Surg Oncol       Date:  2016-02-04

7.  A phase I trial of oxaliplatin for intraperitoneal hyperthermic chemoperfusion for the treatment of peritoneal surface dissemination from colorectal and appendiceal cancers.

Authors:  John H Stewart; Perry Shen; Greg Russell; Joyce Fenstermaker; Libby McWilliams; Faith M Coldrun; Keith E Levine; Bradley T Jones; Edward A Levine
Journal:  Ann Surg Oncol       Date:  2008-05-21       Impact factor: 5.344

8.  Intraperitoneal chemotherapy for peritoneal surface malignancy: experience with 1,000 patients.

Authors:  Edward A Levine; John H Stewart; Perry Shen; Gregory B Russell; Brian L Loggie; Konstantinos I Votanopoulos
Journal:  J Am Coll Surg       Date:  2013-12-21       Impact factor: 6.113

9.  Current Management of Peritoneal Carcinomatosis From Colorectal Cancer: The Role of Cytoreductive Surgery and Hyperthermic Peritoneal Chemoperfusion.

Authors:  Ibrahim Nassour; Patricio M Polanco
Journal:  Curr Colorectal Cancer Rep       Date:  2017-04-08

10.  Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C.

Authors:  Laura A Lambert; Terri S Armstrong; J Jack Lee; Suyu Liu; Matthew H G Katz; Cathy Eng; Robert A Wolff; Melissa L Tortorice; Pier Tansey; Santiago Gonzalez-Moreno; Donald H Lambert; Paul F Mansfield
Journal:  Ann Surg Oncol       Date:  2009-05-28       Impact factor: 5.344

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.